Kyrollis Attalla has identified TIM-3 and TIGIT as promising targets for monotherapy or combination therapy with other immune checkpoint inhibitors in patients with urothelial cancer of the bladder. This evidence concerns the gene TIGIT and bladder transitional cell carcinoma.